Vol 7, No 5 (October 2016): Journal of Gastrointestinal Oncology (Genetic Diversity of Gastrointestinal Malignancies and Emerging Targets: A New World Order)

Review Article

Clinical applications of liquid biopsies in gastrointestinal oncology
Jason Zhu, John H. Strickler
RAS and BRAF in metastatic colorectal cancer management
Jun Gong, May Cho, Marwan Fakih
Beyond RAS and BRAF: a target rich disease that is ripe for picking
Tyler Friedrich, Stephen Leong, Christopher H. Lieu
Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others
Manojkumar Bupathi, Christina Wu
Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach
Van Morris, Cathy Eng
Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?
Namrata Vijayvergia, Steven J. Cohen
Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?
Min Yuen Teo, Eileen M. O’Reilly
The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyond
Ciara M. Kelly, Yelena Y. Janjigian
Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers
Jimmy Hwang
The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1
Zhaohui Jin, Harry H. Yoon
The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?
Sumera Rizvi, Mitesh J. Borad
Molecular profiling of biliary tract cancer: a target rich disease
Apurva Jain, Milind Javle
Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?
Michael S. Lee, Bert H. O’Neil